{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T12:32:04Z","timestamp":1742646724788,"version":"3.28.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00381-024-06491-9","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:02:01Z","timestamp":1718600521000},"page":"3263-3275","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy for pediatric low-grade gliomas"],"prefix":"10.1007","volume":"40","author":[{"given":"Ian F.","family":"Pollack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Felker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Frederico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itay","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Kohanbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"6491_CR1","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","volume":"68","author":"JH Wisoff","year":"2011","unstructured":"Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, Holmes EJ, Kun LE (2011) Primary neurosurgery for pediatric low-grade astrocytomas: a prospective multi-institutional study from the Children\u2019s Oncology Group. Neurosurgery 68:1548\u20131555","journal-title":"Neurosurgery"},{"key":"6491_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro-Oncology 23:1231\u20131251","journal-title":"Neuro-Oncology"},{"key":"6491_CR3","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1056\/NEJMra2116344","volume":"386","author":"AR Cohen","year":"2022","unstructured":"Cohen AR (2022) Brain tumors in Children. N Engl J Med 386:1922\u20131931","journal-title":"N Engl J Med"},{"key":"6491_CR4","doi-asserted-by":"publisher","first-page":"1346949","DOI":"10.3389\/fonc.2023.1346949","volume":"13","author":"GM Yvone","year":"2023","unstructured":"Yvone GM, Breunig JJ (2023) Pediatric low-grade glioma models: advances and ongoing challenges. Front Oncol 13:1346949","journal-title":"Front Oncol"},{"key":"6491_CR5","first-page":"526","volume":"8","author":"S Hirsch","year":"2021","unstructured":"Hirsch S, Dikow N, Pfister SM, Pajtler KW (2021) Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations. Neurooncol Pract 8:526\u2013538","journal-title":"Neurooncol Pract"},{"key":"6491_CR6","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"DT Jones","year":"2008","unstructured":"Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673\u20138677","journal-title":"Cancer Res"},{"key":"6491_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1172\/JCI33656","volume":"118","author":"S Pfister","year":"2008","unstructured":"Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G et al (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118:1739\u20131749","journal-title":"J Clin Invest"},{"key":"6491_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/neuonc\/noaa077","volume":"22","author":"K Fukuoka","year":"2020","unstructured":"Fukuoka K, Mamatjan Y, Tatevossian R, Zapotocky M, Ryall S, Stucklin AG, Bennett J, Nobre LF, Arnoldo A, Luu B, Wen J, Zhu K, Leon A, Torti D, Pugh TJ, Hazrati LN, Laperriere N, Drake J, Rutka JT et al (2020) Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology 22:1474\u20131483","journal-title":"Neuro-Oncology"},{"key":"6491_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/neuonc\/noab138","volume":"23","author":"T Milde","year":"2021","unstructured":"Milde T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, Eberhart CG, Gutmann DH (2021) Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro-Oncology 23:1634\u20131646","journal-title":"Neuro-Oncology"},{"key":"6491_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/ng.2682","volume":"45","author":"DT Jones","year":"2013","unstructured":"Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927\u2013932","journal-title":"Nat Genet"},{"key":"6491_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","volume":"22","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH (2020) Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology 22:773\u2013784","journal-title":"Neuro-Oncology"},{"key":"6491_CR12","first-page":"750","volume":"19","author":"RJ Packer","year":"2017","unstructured":"Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A et al (2017) Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology 19:750\u2013761","journal-title":"Neuro-Oncology"},{"key":"6491_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","volume":"30","author":"JL Ater","year":"2012","unstructured":"Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 30:2641\u20132647","journal-title":"J Clin Oncol"},{"key":"6491_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11060-010-0151-7","volume":"100","author":"KK Mishra","year":"2010","unstructured":"Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA (2010) Phase II TPDCV protocol for pediatric low-grade hypothalamic\/chiasmatic gliomas: 15-year update. J Neuro-Oncol 100:121\u2013127","journal-title":"J Neuro-Oncol"},{"key":"6491_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","volume":"86","author":"RJ Packer","year":"1997","unstructured":"Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747\u2013754","journal-title":"J Neurosurg"},{"key":"6491_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358\u20131363","journal-title":"J Clin Oncol"},{"key":"6491_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","volume":"81","author":"AK Gnekow","year":"2017","unstructured":"Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio P, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL, of the Low Grade Glioma C, the participating c (2017) A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low grade glioma - a final report. Eur J Cancer 81:206\u2013225","journal-title":"Eur J Cancer"},{"key":"6491_CR18","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","volume":"34","author":"A Lassaletta","year":"2016","unstructured":"Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, Pond GR, Poskitt K, Keene D, Johnston DL, Eisenstat DD, Krishnatry R, Mistry M, Arnoldo A, Ramaswamy V et al (2016) Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol 34:3537\u20133543","journal-title":"J Clin Oncol"},{"key":"6491_CR19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","volume":"24","author":"PMK de Blank","year":"2022","unstructured":"de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ et al (2022) MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro-Oncology 24:1845\u20131856","journal-title":"Neuro-Oncology"},{"key":"6491_CR20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM et al (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology 19:1135\u20131144","journal-title":"Neuro-Oncology"},{"key":"6491_CR21","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","volume":"23","author":"J Fangusaro","year":"2021","unstructured":"Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Campagne O, Banerjee A, Gururangan S, Kilburn LB, Goldman S, Qaddoumi I, Baxter P, Vezina G, Bregman C, Patay Z, Jones JY, Stewart CF, Fisher MJ et al (2021) A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncology 23:1777\u20131788","journal-title":"Neuro-Oncology"},{"key":"6491_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW et al (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011\u20131022","journal-title":"Lancet Oncol"},{"key":"6491_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, Osterloh L, Tan E, Choi J, Russo M, Fox E (2023) Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol 41:664\u2013674","journal-title":"J Clin Oncol"},{"key":"6491_CR24","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, Geoerger B, Hingorani P, Dunkel IJ, Russo MW, Tseng L, Dasgupta K, Gasal E, Whitlock JA, Kieran MW (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study. Clin Cancer Res 25:7303\u20137311","journal-title":"Clin Cancer Res"},{"key":"6491_CR25","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","volume":"133","author":"A Bernstein","year":"2019","unstructured":"Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, Glantz M (2019) Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. J Neurosurg 133:1704\u20131709","journal-title":"J Neurosurg"},{"key":"6491_CR26","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garre ML, Hara J, Plant-Fox A, Aerts I, Locatelli F, van der Lugt J, Papusha L, Sahm F, Tabori U, Cohen KJ, Packer RJ, Witt O, Sandalic L, Bento Pereira da Silva A, Russo M, Hargrave DR (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389:1108\u20131120","journal-title":"N Engl J Med"},{"key":"6491_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, Driever PH, Bailey S, Perreault S, McCowage G, Waanders AJ, Ziegler DS, Witt O, Baxter PA, Kang HJ, Hassall TE, Han JW, Hargrave D, Franson AT et al (2024) The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30:207\u2013217","journal-title":"Nat Med"},{"issue":"569-583","key":"6491_CR28","first-page":"e565","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37(569-583):e565","journal-title":"Cancer Cell"},{"key":"6491_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397\u2013405","journal-title":"Acta Neuropathol"},{"key":"6491_CR30","doi-asserted-by":"publisher","first-page":"95516","DOI":"10.18632\/oncotarget.20764","volume":"8","author":"A Bongaarts","year":"2017","unstructured":"Bongaarts A, Giannikou K, Reinten RJ, Anink JJ, Mills JD, Jansen FE, Spliet GMW, den Dunnen WFA, Coras R, Blumcke I, Paulus W, Scholl T, Feucht M, Kotulska K, Jozwiak S, Buccoliero AM, Caporalini C, Giordano F, Genitori L et al (2017) Subependymal giant cell astrocytomas in tuberous sclerosis complex have consistent TSC1\/TSC2 biallelic inactivation, and no BRAF mutations. Oncotarget 8:95516\u201395529","journal-title":"Oncotarget"},{"key":"6491_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","volume":"49","author":"J Roth","year":"2013","unstructured":"Roth J, Roach ES, Bartels U, Jozwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ (2013) Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 49:439\u2013444","journal-title":"Pediatr Neurol"},{"key":"6491_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pediatrneurol.2017.04.008","volume":"72","author":"MS Arroyo","year":"2017","unstructured":"Arroyo MS, Krueger DA, Broomall E, Stevenson CB, Franz DN (2017) Acute management of symptomatic subependymal giant cell astrocytoma with everolimus. Pediatr Neurol 72:81\u201385","journal-title":"Pediatr Neurol"},{"key":"6491_CR33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","volume":"78","author":"DN Franz","year":"2015","unstructured":"Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA (2015) Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol 78:929\u2013938","journal-title":"Ann Neurol"},{"key":"6491_CR34","first-page":"359","volume":"7","author":"VM Lu","year":"2020","unstructured":"Lu VM, Welby JP, Nesvick CL, Daniels DJ (2020) Efficacy and safety of bevacizumab in progressive pediatric low-grade glioma: a systematic review and meta-analysis of outcome rates. Neurooncol Pract 7:359\u2013368","journal-title":"Neurooncol Pract"},{"key":"6491_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/neuonc\/not154","volume":"16","author":"S Gururangan","year":"2014","unstructured":"Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro-Oncology 16:310\u2013317","journal-title":"Neuro-Oncology"},{"key":"6491_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","volume":"29","author":"KE Warren","year":"2011","unstructured":"Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE (2011) Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 29:324\u2013329","journal-title":"J Clin Oncol"},{"key":"6491_CR37","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/pbc.24297","volume":"60","author":"EI Hwang","year":"2013","unstructured":"Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ (2013) Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer 60:776\u2013782","journal-title":"Pediatr Blood Cancer"},{"key":"6491_CR38","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s00381-020-04704-5","volume":"36","author":"RJ Packer","year":"2020","unstructured":"Packer RJ, Vezina G (2020) New treatment modalities in NF-related neuroglial tumors. Childs Nerv Syst 36:2377\u20132384","journal-title":"Childs Nerv Syst"},{"key":"6491_CR39","first-page":"vdac182","volume":"5","author":"JW Tsai","year":"2023","unstructured":"Tsai JW, Choi JJ, Ouaalam H, Murillo EA, Yeo KK, Vogelzang J, Sousa C, Woods JK, Ligon KL, Warfield SK, Bandopadhayay P, Cooney TM (2023) Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neurooncol Adv 5:vdac182","journal-title":"Neurooncol Adv"},{"key":"6491_CR40","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijrobp.2004.06.012","volume":"61","author":"KJ Marcus","year":"2005","unstructured":"Marcus KJ, Goumnerova L, Billett AL, Lavally B, Scott RM, Bishop K, Xu R, Young Poussaint T, Kieran M, Kooy H, Pomeroy SL, Tarbell NJ (2005) Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys 61:374\u2013379","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6491_CR41","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.004","volume":"103","author":"JM Cherlow","year":"2019","unstructured":"Cherlow JM, Shaw DWW, Margraf LR, Bowers DC, Huang J, Fouladi M, Onar-Thomas A, Zhou T, Pollack IF, Gajjar A, Kessel SK, Cullen PL, McMullen K, Wellons JC, Merchant TE (2019) Conformal radiation therapy for pediatric patients with low-grade glioma: results from the Children\u2019s Oncology Group Phase 2 Study ACNS0221. Int J Radiat Oncol Biol Phys 103:861\u2013868","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6491_CR42","first-page":"68","volume":"34","author":"PB Dirks","year":"1994","unstructured":"Dirks PB, Jay V, Becker LE, Drake JM, Humphreys RP, Hoffman HJ, Rutka JT (1994) Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 34:68\u201378","journal-title":"Neurosurgery"},{"key":"6491_CR43","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1038\/s41467-020-18070-y","volume":"11","author":"Y Grabovska","year":"2020","unstructured":"Grabovska Y, Mackay A, O'Hare P, Crosier S, Finetti M, Schwalbe EC, Pickles JC, Fairchild AR, Avery A, Cockle J, Hill R, Lindsey J, Hicks D, Kristiansen M, Chalker J, Anderson J, Hargrave D, Jacques TS, Straathof K et al (2020) Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nat Commun 11:4324","journal-title":"Nat Commun"},{"key":"6491_CR44","doi-asserted-by":"publisher","unstructured":"Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vel\u00e1zquez Vega JE, Schniederjan M, Dhodapkar K (2020) Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. J Immunother Cancer 2020 Aug;8(2):e001066. https:\/\/doi.org\/10.1136\/jitc-2020-001066","DOI":"10.1136\/jitc-2020-001066"},{"key":"6491_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-017-2079-7","volume":"67","author":"Q Liu","year":"2018","unstructured":"Liu Q, Zhu H, Liu Y, Musetti S, Huang L (2018) BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunol Immunother 67:299\u2013310","journal-title":"Cancer Immunol Immunother"},{"key":"6491_CR46","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3389\/fimmu.2019.03045","volume":"10","author":"PG Kemps","year":"2019","unstructured":"Kemps PG, Zondag TC, Steenwijk EC, Andriessen Q, Borst J, Vloemans S, Roelen DL, Voortman LM, Verdijk RM, van Noesel CJM, Cleven AHG, Hawkins C, Lang V, de Ru AH, Janssen GMC, Haasnoot GW, Franken K, van Eijk R, Solleveld-Westerink N et al (2019) Apparent lack of BRAF(V600E) derived HLA class I presented neoantigens hampers neoplastic cell targeting by CD8(+) T cells in Langerhans cell histiocytosis. Front Immunol 10:3045","journal-title":"Front Immunol"},{"key":"6491_CR47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","volume":"128","author":"JR Veatch","year":"2018","unstructured":"Veatch JR, Lee SM, Fitzgibbon M, Chow IT, Jesernig B, Schmitt T, Kong YY, Kargl J, Houghton AM, Thompson JA, McIntosh M, Kwok WW, Riddell SR (2018) Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest 128:1563\u20131568","journal-title":"J Clin Invest"},{"key":"6491_CR48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV (2024) Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med 390:1290\u20131298","journal-title":"N Engl J Med"},{"key":"6491_CR49","doi-asserted-by":"publisher","unstructured":"Muller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF (2018) Kohanbash G (2018) Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. JCI Insight 3(7):e98791. https:\/\/doi.org\/10.1172\/jci.insight.98791","DOI":"10.1172\/jci.insight.98791"},{"key":"6491_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","volume":"3","author":"EI Hwang","year":"2022","unstructured":"Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF (2022) The current landscape of immunotherapy for pediatric brain tumors. Nat Can 3:11\u201324","journal-title":"Nat Can"},{"key":"6491_CR51","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/neuonc\/now026","volume":"18","author":"IF Pollack","year":"2016","unstructured":"Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H (2016) Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro-Oncology 18:1157\u20131168","journal-title":"Neuro-Oncology"},{"key":"6491_CR52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MPH.0000000000000047","volume":"36","author":"LL Hartman","year":"2014","unstructured":"Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL (2014) Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 36:451\u2013457","journal-title":"J Pediatr Hematol Oncol"},{"key":"6491_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.omto.2020.12.012","volume":"20","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guo X, Gao L, Wang Y, Guo Y, Xing B, Ma W (2021) Classification of pediatric gliomas based on immunological profiling: implications for immunotherapy strategies. Mol Ther Oncolytics 20:34\u201347","journal-title":"Mol Ther Oncolytics"},{"key":"6491_CR54","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","volume":"32","author":"IF Pollack","year":"2014","unstructured":"Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H (2014) Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 32:2050\u20132058","journal-title":"J Clin Oncol"},{"key":"6491_CR55","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11060-008-9693-3","volume":"91","author":"N Butowski","year":"2009","unstructured":"Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD (2009) A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neuro-Oncol 91:175\u2013182","journal-title":"J Neuro-Oncol"},{"key":"6491_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-008-9705-3","volume":"91","author":"N Butowski","year":"2009","unstructured":"Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM (2009) A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neuro-Oncol 91:183\u2013189","journal-title":"J Neuro-Oncol"},{"key":"6491_CR57","doi-asserted-by":"crossref","unstructured":"Buonaguro L, Tagliamonte M (2023) Peptide-based vaccine for cancer therapies. Front Immunol:14","DOI":"10.3389\/fimmu.2023.1210044"},{"key":"6491_CR58","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357\u20132368","journal-title":"J Exp Med"},{"key":"6491_CR59","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4049\/jimmunol.163.1.184","volume":"163","author":"S Matsui","year":"1999","unstructured":"Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163:184\u2013193","journal-title":"J Immunol"},{"key":"6491_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-008-9566-9","volume":"88","author":"H Okada","year":"2008","unstructured":"Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF (2008) Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neuro-Oncol 88:245\u2013250","journal-title":"J Neuro-Oncol"},{"key":"6491_CR61","first-page":"2851","volume":"8","author":"F Okano","year":"2002","unstructured":"Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8:2851\u20132855","journal-title":"Clin Cancer Res"},{"key":"6491_CR62","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/0008-5472.CAN-05-3825","volume":"66","author":"F Nishimura","year":"2006","unstructured":"Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H (2006) Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res 66:4478\u20134487","journal-title":"Cancer Res"},{"key":"6491_CR63","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1593\/neo.05277","volume":"7","author":"M Hatano","year":"2005","unstructured":"Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H (2005) EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 7:717\u2013722","journal-title":"Neoplasia"},{"key":"6491_CR64","first-page":"5964","volume":"61","author":"MH Andersen","year":"2001","unstructured":"Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964\u20135968","journal-title":"Cancer Res"},{"key":"6491_CR65","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00262-005-0102-x","volume":"55","author":"M Wobser","year":"2005","unstructured":"Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC (2005) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55:1294\u20131298","journal-title":"Cancer Immunol Immunother"},{"key":"6491_CR66","first-page":"3012","volume":"7","author":"CL Slingluff Jr","year":"2001","unstructured":"Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG (2001) Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7:3012\u20133024","journal-title":"Clin Cancer Res"},{"key":"6491_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-5-10","volume":"5","author":"X Zhu","year":"2007","unstructured":"Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10","journal-title":"J Transl Med"},{"key":"6491_CR68","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"H Okada","year":"2011","unstructured":"Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330\u2013336","journal-title":"J Clin Oncol"},{"key":"6491_CR69","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ern.11.49","volume":"11","author":"H Okada","year":"2011","unstructured":"Okada H, Pollack IF (2011) Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother 11:619\u2013622","journal-title":"Expert Rev Neurother"},{"key":"6491_CR70","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542","journal-title":"Lancet Oncol"},{"key":"6491_CR71","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17:261\u2013279","journal-title":"Nat Rev Drug Discov"},{"key":"6491_CR72","doi-asserted-by":"publisher","unstructured":"Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M (2021) Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front Oncol 11:672508. https:\/\/doi.org\/10.3389\/fonc.2021.672508","DOI":"10.3389\/fonc.2021.672508"},{"key":"6491_CR73","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.ebiom.2023.104963","volume":"100","author":"Z Xiong","year":"2024","unstructured":"Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G (2024) Glioblastoma vaccines: past, present, and opportunities. EBioMedicine 100:104963","journal-title":"EBioMedicine"},{"key":"6491_CR74","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1021\/acs.nanolett.8b02179","volume":"18","author":"EJ Sayour","year":"2018","unstructured":"Sayour EJ, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, Wummer B, Moore G, Castillo-Caro P, Fredenburg K, Sarkisian MR, Huang J, Deleyrolle LP, Sahay B, Carrera-Justiz S, Mendez-Gomez HR, Mitchell DA (2018) Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett 18:6195\u20136206","journal-title":"Nano Lett"},{"key":"6491_CR75","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500\u20132501","journal-title":"N Engl J Med"},{"key":"6491_CR76","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","volume":"25","author":"IJ Dunkel","year":"2023","unstructured":"Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, Andre N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K (2023) Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro-Oncology 25:1530\u20131545","journal-title":"Neuro-Oncology"},{"key":"6491_CR77","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, Prolo LM, Batchelor TT, Campen CJ, Davis KL, Gust J, Lim M, Majzner RG, Park JR, Partap S, Ramakrishna S, Richards R, Schultz L, Vitanza NA et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29:803\u2013810","journal-title":"Nat Med"},{"key":"6491_CR78","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603:934\u2013941","journal-title":"Nature"},{"key":"6491_CR79","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, Albert CM, Browd SR, Hauptman JS, Lee A et al (2023) Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov 13:114\u2013131","journal-title":"Cancer Discov"},{"key":"6491_CR80","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133\u2013151","journal-title":"J Immunother"},{"issue":"5","key":"6491_CR81","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadlowsky JK, Christensen S, Oner BS, Plesa G, Brennan A et al (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30(5):1320\u20131329","journal-title":"Nat Med"},{"key":"6491_CR82","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, Masud N, Fell G, Mo X, Yilmaz AS, Grant J, Zhang A, Bernstock JD, Torio E, Ito H, Liu J, Shono N, Nowicki MO, Triggs D et al (2023) Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature 623:157\u2013166","journal-title":"Nature"},{"key":"6491_CR83","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD (2018) Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150\u2013161","journal-title":"N Engl J Med"},{"key":"6491_CR84","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, Khakoo Y, Karajannis MA, Woodling K, Palmer JD et al (2021) Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med 384:1613\u20131622","journal-title":"N Engl J Med"},{"key":"6491_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH, Gunn MD, Fecci PE, Ashley DM (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20:12\u201325","journal-title":"Nat Rev Cancer"},{"key":"6491_CR86","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nn.3161","volume":"15","author":"SS Ousman","year":"2012","unstructured":"Ousman SS, Kubes P (2012) Immune surveillance in the central nervous system. Nat Neurosci 15:1096\u20131101","journal-title":"Nat Neurosci"},{"key":"6491_CR87","doi-asserted-by":"publisher","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","volume":"380","author":"G Castellani","year":"2023","unstructured":"Castellani G, Croese T, Peralta Ramos JM, Schwartz M (2023) Transforming the understanding of brain immunity. Science 380:eabo7649","journal-title":"Science"},{"key":"6491_CR88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","volume":"577","author":"E Song","year":"2020","unstructured":"Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, Alitalo K, Thomas JL, Iwasaki A (2020) VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. Nature 577:689\u2013694","journal-title":"Nature"},{"key":"6491_CR89","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1530\/VB-19-0033","volume":"2","author":"L Marchetti","year":"2020","unstructured":"Marchetti L, Engelhardt B (2020) Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc Biol 2:H1\u2013H18","journal-title":"Vasc Biol"},{"key":"6491_CR90","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s40478-019-0803-6","volume":"7","author":"M Martinez-Lage","year":"2019","unstructured":"Martinez-Lage M, Lynch TM, Bi Y, Cocito C, Way GP, Pal S, Haller J, Yan RE, Ziober A, Nguyen A, Kandpal M, O'Rourke DM, Greenfield JP, Greene CS, Davuluri RV, Dahmane N (2019) Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun 7:203","journal-title":"Acta Neuropathol Commun"},{"key":"6491_CR91","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41467-020-16682-y","volume":"11","author":"LH Chen","year":"2020","unstructured":"Chen LH, Pan C, Diplas BH, Xu C, Hansen LJ, Wu Y, Chen X, Geng Y, Sun T, Sun Y, Zhang P, Wu Z, Zhang J, Li D, Zhang Y, Wu W, Wang Y, Li G, Yang J et al (2020) The integrated genomic and epigenomic landscape of brainstem glioma. Nat Commun 11:3077","journal-title":"Nat Commun"},{"key":"6491_CR92","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","volume":"21","author":"S Darmanis","year":"2017","unstructured":"Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, Samghababi P, Zhang Y, Neff N, Kowarsky M, Caneda C, Li G, Chang SD, Connolly ID, Li Y, Barres BA, Gephart MH, Quake SR (2017) Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 21:1399\u20131410","journal-title":"Cell Rep"},{"issue":"1962-1985","key":"6491_CR93","first-page":"e1931","volume":"183","author":"F Petralia","year":"2020","unstructured":"Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, Calinawan A, Whiteaker JR, Colaprico A, Stathias V, Omelchenko T, Song X, Raman P, Guo Y, Brown MA et al (2020) Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell 183(1962-1985):e1931","journal-title":"Cell"},{"key":"6491_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13073-023-01219-x","volume":"15","author":"A Nabbi","year":"2023","unstructured":"Nabbi A, Beck P, Delaidelli A, Oldridge DA, Sudhaman S, Zhu K, Yang SYC, Mulder DT, Bruce JP, Paulson JN, Raman P, Zhu Y, Resnick AC, Sorensen PH, Sill M, Brabetz S, Lambo S, Malkin D, Johann PD et al (2023) Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours. Genome Med 15:67","journal-title":"Genome Med"},{"key":"6491_CR95","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/2326-6066.CIR-15-0030","volume":"3","author":"SD Bradley","year":"2015","unstructured":"Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizee G (2015) BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. Cancer Immunol Res 3:602\u2013609","journal-title":"Cancer Immunol Res"},{"key":"6491_CR96","doi-asserted-by":"publisher","first-page":"e22890","DOI":"10.4161\/onci.22890","volume":"2","author":"B Sapkota","year":"2013","unstructured":"Sapkota B, Hill CE, Pollack BP (2013) Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology 2:e22890","journal-title":"Oncoimmunology"},{"key":"6491_CR97","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","volume":"4","author":"EJ Brea","year":"2016","unstructured":"Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA (2016) Kinase regulation of human MHC class I molecule expression on cancer cells. Cancer Immunol Res 4:936\u2013947","journal-title":"Cancer Immunol Res"},{"key":"6491_CR98","doi-asserted-by":"publisher","unstructured":"Frederico SC, Sharma N, Darling C, Taori S, Dubinsky AC, Zhang X, Raphael I, Kohanbash G (2024) Myeloid cells as potential targets for immunotherapy in pediatric gliomas. Front Pediatr 12. https:\/\/doi.org\/10.3389\/fped.2024.1346493","DOI":"10.3389\/fped.2024.1346493"},{"key":"6491_CR99","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.neo.2022.100857","volume":"36","author":"N Manoharan","year":"2023","unstructured":"Manoharan N, Liu KX, Mueller S, Haas-Kogan DA, Bandopadhayay P (2023) Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era. Neoplasia 36:100857","journal-title":"Neoplasia"},{"key":"6491_CR100","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.2147\/IJGM.S323576","volume":"14","author":"M Khan","year":"2021","unstructured":"Khan M, Li X, Yan M, Li Z, Yang H, Liao G (2021) Efficacy and safety of actively personalized neoantigen vaccination in the management of newly diagnosed glioblastoma: a systematic review. Int J Gen Med 14:5209\u20135220","journal-title":"Int J Gen Med"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06491-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-024-06491-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06491-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:11:51Z","timestamp":1729840311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-024-06491-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6491"],"URL":"https:\/\/doi.org\/10.1007\/s00381-024-06491-9","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"type":"print","value":"0256-7040"},{"type":"electronic","value":"1433-0350"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article. No new data are presented. The study does include a summary of data included in University of Pittsburgh IRB PRO08030085, and signed consent was obtained from all participants. This study, among all others referenced in this review article, was previously published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}